Maternal and Cord Mitochondrial DNA Heteroplasmy, Copy Number Linked to Preterm Birth

Preterm birth (PTB)—delivery before 37 weeks—remains a major contributor to neonatal illness and long-term developmental risk. Despite decades of research, the biological processes that tip pregnancy toward early delivery are still incompletely mapped. A new study in Pediatric Research now adds mitochondrial biology to the shortlist of mechanisms worth closer attention, focusing on how variation in maternal and fetal mitochondrial DNA (mtDNA) may influence timing of birth.

Mitochondria, the cell’s energy hubs, rely on mtDNA integrity and appropriate copy number to meet metabolic demands. Two metrics capture different aspects of mtDNA status: heteroplasmy, the fraction of mtDNA molecules carrying variants, and mtDNA copy number (mtDNA-CN), a proxy for mitochondrial abundance or replication. Because the maternal–fetal transition involves intense energetic and oxidative shifts, investigators hypothesized that both measures—and their combined patterns—could relate to PTB risk.

The researchers evaluated mtDNA heteroplasmy and mtDNA-CN in maternal blood and in cord blood, treating them as independent exposures. Importantly, they also tested “joint” associations, asking whether specific combinations of mitochondrial features in both compartments correspond more strongly with early birth than either feature alone.

By examining maternal and cord blood together, the study aimed to distinguish signals originating from the mother’s physiological environment from those reflecting placental or fetal mitochondrial state. This dual sampling strategy is critical: maternal blood may reflect systemic stresses, while cord blood can capture downstream effects closer to the fetus.

Although the study’s full statistical details are not summarized here, the central premise is clear: mitochondrial variation is not only measurable but potentially clinically informative. If heteroplasmy and copy number show distinct or synergistic relationships with PTB, it could indicate that mitochondrial dysfunction operates through multiple, interacting pathways rather than a single defect.

The findings support the idea that inadequate mitochondrial performance—through either altered genomic variation or insufficient/abnormal mitochondrial quantity—may contribute to impaired fetal growth trajectories and placental insufficiency, both established precursors to PTB.

Equally noteworthy is the implication for biomarker development. If reproducible associations are confirmed, maternal and cord blood mitochondrial metrics could be used to refine risk stratification beyond conventional clinical predictors.

Overall, the study frames PTB as a disorder with metabolic and genomic underpinnings, emphasizing that mitochondrial genetics may help explain why some pregnancies begin to falter early. Future work will need to validate these patterns in larger cohorts and clarify whether the observed mtDNA signatures reflect cause, consequence, or both.